Abstract: The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

Abstract: The present invention relates to the use of an aza-BODIPY fluorophore compound as a contrast agent in the optical window ranging from 1000 to 1700 nm. The invention also relates to the use, as a contrast agent, of a composition comprising said fluorophore compound and a pharmaceutically acceptable excipient and/or a solvent, in a kit comprising an injection system and said fluorophore or said composition, and also to a method for identifying a biological target (such as a healthy or tumour cell, a protein, DNA, RNA, for example).

Abstract: The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

Abstract: The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

Abstract: The present invention relates to a peptide comprising an amino acid sequence at least 85% identical to the amino acid sequence as shown in SEQ ID NO. 1, wherein the residues Lys905, Arg909, and Arg912 contained therein are present, for use as a medicament, in particular for its use as an inhibitor of FGF-2 induced angiogenesis.

Abstract: The invention concerns the field of molecular probe architecture for in vivo imaging. More particularly, the invention concerns molecular constructs providing an imaging function activable in intracellular environment. The inventive fluorescence probes enable in particular images of certain targeted tissues to be formed, while maintaining a low background noise level and, preferably, while obtaining at the targeted tissue, an imaging signal increasing in time.

Abstract: The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

Abstract: A fluorescent enzymatic substrate including a backbone saccharide nature having at least one saccharide unit. The saccharide unit includes a fluorophore F1 and an inhibitor I1 of the fluorescence of F1. The fluorophore F1 and the inhibitor I1, either directly or by the spacer arms B1 and B2, respectively, when at least one B1 and B2 is present, are grafted on the same saccharide unit of the backbone saccharide. One of th groups is F1 and I1 grafted in the anomeric position 1 of the saccharide unit.

Abstract: A method for preparing a grafted homodetic cyclopeptide forming a framework that defines a grafted upper face and grafted lower face, including synthesizing a linear peptide from modified or unmodified amino acids, some of which carry orthogonal protective groups; intramolecular cyclizing the resulting protected linear peptide; substituting some or all of orthogonal protective groups with a protected precursor; and grafting at least one molecule of interest onto one and/or the other face of the framework via an oxime bond.

Abstract: The invention concerns saccharide type fluorescent enzymatic substrates comprising on the same saccharide unit a fluorophor F1 and an inhibitor of the fluorescence of F1, and their use for preparing a diagnostic reagent for in vivo functional imaging, as well as a diagnostic reagent containing at least such an enzymatic substrate.

Abstract: The invention concerns the field of molecular probe architecture for in vivo imaging. More particularly, the invention concerns molecular constructs providing an imaging function activable in intracellular environment, said constructs being further bound to a vector which enables certain cells to be targeted, and said cells to be internalized. The inventive fluorescence probes enable in particular images of certain targeted tissues to be formed, while maintaining a low background noise level and, preferably, while obtaining at the targeted tissue, an imaging signal increasing in time.

Abstract: A method for preparing a grafted homodetic cyclopeptide froming a framework that defines a grafted upper face and grafted lower face, including synthesizing a linear peptide from modified or unmodified amino acids, some of which carry orthogonal protective groups; intramolecular cyclizing the resulting protected linear peptide; substituting some or all of orthogonal protective groups with a protected precursor; and grafting at least one molecule of interest onto one and/or the other face of the framework via an oxime bond.